E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
osteoarthritis of the hands |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the global pain intensity in the target hand measured on a 100 mm VAS, respectively after 2 and 4 weeks treatment. |
|
E.2.2 | Secondary objectives of the trial |
The secondary outcome measures are: The response to treatment, defined by the OARSI (OsteoArthritis Research Society International) and the OMERACT (Outcome Measures in Rheumatology) committees The change in the AUSCAN pain subscale from baseline to respectively 2 and 4 weeks treatment. The response to treatment, defined as 30% decrease in the AUSCAN pain subscale from baseline to 2 and 4 weeks. The change in AUSCAN joint stiffness, and physical function subscales from baseline to respectively 2 and 4 weeks treatment. The change in palpation pain evaluated by the Ritchie scale for the target hand from baseline to respectively 2 and 4 weeks treatment. The change in grip strength measured by dynamometry for the target hand from baseline to respectively 2 and 4 weeks treatment. The use of paracetamol as rescue medication measured by checking compliance, from baseline to respectively 2 and 4 weeks treatment
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients of either sex - Age > 30 years - Providing of written informed consent. - Patients with hand osteoarthritis according to the diagnostic criteria of the American College of Rheumatology - Patients with primary (non-erosive and erosive OA) and post-traumatic (due only to remote [> 6 months ago] trauma). - Patients with thumb OA - On entry, a global hand pain score in the target hand of at least 40 mm on a 100 mm visual analogue scale (VAS), after withdrawal of other analgesic/anti-inflammatory medications. - Patients who are taking paracetamol (as rescue medication) are allowed to participate in the trial. - Minimum symptom duration: pain should have been present for at least half of the days in the previous month (i.e. pain should have been present for at least 15 days in the previous month) and for at least 48 hours prior to inclusion visit (T0). |
|
E.4 | Principal exclusion criteria |
- Patient unable to understand the study procedures and/or not having given written informed consent and/or not wishing to participate in one of the subsequent therapeutic intervention protocols. - Unlikely to co-operate fully in the study. - Alcohol (e.g. more than 28 units per week) or drug abuse. - Pregnancy or breastfeeding women. - Patients with a swollen or warm joint thought to be secondary to gout, pseudogout or sepsis. - Clinically significant medical abnormalities, which would make the patient unsuitable for the study as judged by the investigator. - The patient has a fracture or malignant tumor at the hands. Significant injury to the affected joint within 6 months of trial start. Disease upper extremity joints of sufficient degree to affect assessment of the target joint. Presence of OA secondary to known disorders other that remote (> 6 months ago) trauma. - Poor general health interfering with compliance or assessment - Less than 1 month between the time of IA injection of depocorticosteroid and enrollment. - Less than 6 months between the time of IA injection of a hyaluronate and enrollment. - Patients with symptomatic knee OA. - Use of assistive devices such as a cane or crutch. - Less than 3 months between the treatment with a slow acting drug for symptom relief and enrollment - Concomitant and previous medication: Use (topical, systemic, intra-articular) of hyaluronic acid, glucosamine sulphate, glucosamine HCl, n-acetyl glucosamine and derivatives thereof such as chondroitin sulphate, glycosaminoglycans. Patients who have used previous topical and/or systemic treatment with NSAID’s or analgetica, different from paracetamol, such as ibuprofen, diclofenac, acetyl salicylic acid, piroxicam and indomethacin in a 14 days period prior to the start of the study Patients who have used medications with MMP-inhibitory properties (e.g. tetracyclines or structurally related compounds), or took oral (systemic, > 10 days duration) glucocorticoids in a 28 days period prior to start of the study. Patients who have used compounds containing agents claiming to possess disease/structure modifying properties (e.g. diacerhein, glucosamine and/or chondroitin sulfate containing compounds) in a 28 days period prior to start of the study. - Treatment during the trial with physical and/or occupational therapy. - Known allergy against glucosamine or any of the ingredients in the cream. - Open wounds at the hands. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is: The global pain intensity in the target hand measured on a 100 mm VAS, respectively after 2 and 4 weeks treatment.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial is the date of the last visit of the last patient undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |